Filing Flows › Comparisons › BEAM vs PROK
Beam Therapeutics vs Prokidney: BEAM and PROK compared
Beam Therapeutics is the larger company: $307K of revenue in its latest quarter (Q3 2026) against $150K for Prokidney (Q2 2026). Prokidney is growing faster (-32% against -97% a year earlier).
Where the money goes: BEAM and PROK
Beam Therapeutics (BEAM) · Q3 2026
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart follows the revenue to costs, profit and cash.
Prokidney (PROK) · Q2 2026
Prokidney, Q2 2026: revenue $150K (-32% year over year), net loss $46.4M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
| Beam Therapeutics (BEAM) | Prokidney (PROK) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $307K | $150K |
| Revenue growth, Y/Y | -97% | -32% |
| Operating margin | n/m | n/m |
| Net earnings | −$134M | −$46.4M |
| Operating cash flow | −$111M | −$40.4M |
Questions
Which is bigger, Beam Therapeutics or Prokidney?
Beam Therapeutics is the larger company: $307K of revenue in its latest quarter (Q3 2026) against $150K for Prokidney (Q2 2026).
Is Beam Therapeutics or Prokidney growing faster?
Prokidney is growing faster (-32% against -97% a year earlier).
More: Beam Therapeutics earnings · how Beam Therapeutics makes money · Prokidney earnings · how Prokidney makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.